Advertisement

High expression of peptide receptors as a novel target in gastrointestinal stromal tumours

  • Jean Claude ReubiEmail author
  • Meike Körner
  • Beatrice Waser
  • Luca Mazzucchelli
  • Louis Guillou
Original Article

Abstract

Recent significant advances in understanding the biology of gastrointestinal stromal tumours (GIST) have led to the introduction of a new targeted therapy (imatinib mesylate, Glivec). Hopes of a new era of a specific cancer therapy, however, have been tempered by the recognition that a significant proportion of patients who initially respond to the drug eventually become resistant to it. Given the successful development of peptide receptor scintigraphy and radiotherapy for neuroendocrine tumours, we postulated that a similar approach could offer a valid alternative in the diagnosis and therapy of GIST. Using in vitro receptor autoradiography to measure peptide receptors, we found that 16/19 GIST expressed bombesin subtype 2 receptors, 16/19 expressed vasoactive intestinal peptide subtype 2 receptors (VPAC2) and 12/19 expressed cholecystokinin subtype 2 receptors, in most cases in extremely high densities. All GIST metastases were shown to express two or more of these peptide receptors in very high density. Receptors were also expressed in non-responders to Glivec or after chemo-embolisation. Conversely, somatostatin subtype 2, cholecystokinin subtype 1, bombesin subtype 1 and 3, and neuropeptide Y subtype Y1 and Y2 receptors were not or only rarely expressed. These data represent a strong molecular basis for the use of radiolabelled bombesin, vasoactive intestinal peptide and/or cholecystokinin analogues as targeting agents to localise GIST tumours in patients by in vivo scintigraphy and/or to perform targeted radiotherapy to destroy GIST primaries, metastases and recurrences, including those resistant to Glivec.

Keywords

Gastrointestinal stromal tumours Cancer targeting Peptide receptors Bombesin receptors Cholecystokinin receptors 

Notes

Acknowledgement

We thank Dr. P. Robberecht, Brussels, for the gift of Ro25-1553 and KRL-VIP/GRF. We also thank Mrs. R. Rehmann and V. Eltschinger, Berne, for excellent technical assistance, and Dr. Hanifa Bouzourene for her help in selecting the GIST cases.

References

  1. 1.
    Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259–1269.PubMedGoogle Scholar
  2. 2.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577–580.PubMedGoogle Scholar
  3. 3.
    Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61:8118–8121.PubMedGoogle Scholar
  4. 4.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052–1056.PubMedGoogle Scholar
  5. 5.
    van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421–1423.CrossRefPubMedGoogle Scholar
  6. 6.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472–480.Google Scholar
  7. 7.
    Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459–465.CrossRefPubMedGoogle Scholar
  8. 8.
    Barthe C, Cony-Makhoul P, Melo JV, Mahon JR. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293:2163.Google Scholar
  9. 9.
    von Mehren M, Blanke CD, Joensuu H. High incidence of durable responses induced by imatinib mesylate (imatinib) in patients with unresectable and metastatic gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002; 21:abstract 1608.Google Scholar
  10. 10.
    Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389–427.Google Scholar
  11. 11.
    Kwekkeboom DJ, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704–1713.PubMedGoogle Scholar
  12. 12.
    Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26–34.PubMedGoogle Scholar
  13. 13.
    Valkema R, Jamar F, Jonard P, Bakker WH, Norenberg J, Hadley J, Smith C, Kvols L, Pauwels S, Krenning EP. Targeted radiotherapy with90Y-SMT487 (Octreo Ther): a phase 1 study [abstract]. J Nucl Med 2000; 41 (suppl):111P.Google Scholar
  14. 14.
    Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941–945.PubMedGoogle Scholar
  15. 15.
    Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001; 28:426–434.PubMedGoogle Scholar
  16. 16.
    Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PP, Herder WW, Feelders RA, Eijck CHJ, Jong M, Srinivasan A, Erion JL, Krenning EP. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417–422.PubMedGoogle Scholar
  17. 17.
    Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27:1694–1699.PubMedGoogle Scholar
  18. 18.
    Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S.99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 2003; 30:1378–1382.CrossRefPubMedGoogle Scholar
  19. 19.
    Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, Becker W. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999; 40:1029–1044.PubMedGoogle Scholar
  20. 20.
    Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, Reubi JC, Krenning EP. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000; 27:1312–1317.CrossRefPubMedGoogle Scholar
  21. 21.
    Rettenbacher M, Reubi J. Localization and characterization of neuropeptide receptors in human colon. Naunyn-Schmiedebergs Arch Pharmacol 2001; 364:291–304.CrossRefGoogle Scholar
  22. 22.
    Sternini C, Wong H, Wu V, de Giorgio R, Yang M, Reeve J Jr, Brecha NC, Walsh JH. Somatostatin 2A receptor is expressed by enteric neurons, and by interstitial cells of cajal and enterochromaffin-like cells of the gastrointestinal tract. J Comp Neurol 1997; 386:396–408.CrossRefPubMedGoogle Scholar
  23. 23.
    Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance P receptors in human primary neoplasms: tumoural and vascular localisation. Int J Cancer 1995; 61:786–792.PubMedGoogle Scholar
  24. 24.
    Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997; 57:1377–1386.PubMedGoogle Scholar
  25. 25.
    Reubi JC, Läderach U, Waser B, Gebbers J-O, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000; 60:3105–3112.PubMedGoogle Scholar
  26. 26.
    Reubi JC, Gugger M, Waser B, Schaer JC. Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001; 61:4636–4641.PubMedGoogle Scholar
  27. 27.
    Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[d-TYR(6), beta-ALA(11), PHE(13), NLE(14)] Bombesin(6–14). Clin Cancer Res 2002; 8:1139–1146.PubMedGoogle Scholar
  28. 28.
    Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging 2003; 30:781–793.PubMedGoogle Scholar
  29. 29.
    Behr TM, Béhé MP, Angerstein C, Hüfner M, Becker W. Cholecystokinin (CCK)-B/gastrin-receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer. J Nucl Med 2001; 42 Suppl:157P, No.587.Google Scholar
  30. 30.
    Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, de Neef P, Waelbroeck M, Robberecht P. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 1997; 18:403–408.CrossRefPubMedGoogle Scholar
  31. 31.
    Reubi JC, Waser B, Läderach U, Stettler C, Friess H, Halter F, Schmassmann A. Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the human stomach and gallbladder. Gastroenterology 1997; 112:1197–1205.PubMedGoogle Scholar
  32. 32.
    Raderer M, Kurtaran A, Hejna M, Vorbeck F, Angelberger P, Scheithauer W, Virgolini I.123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer 1998; 78:1–5.Google Scholar
  33. 33.
    Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002; 32:97–109.PubMedGoogle Scholar
  34. 34.
    Van De Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, Thierens H. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 2001; 42:1722–1727.PubMedGoogle Scholar
  35. 35.
    Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003; 9:495–509.PubMedGoogle Scholar
  36. 36.
    Baldwin GS. The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J Gastroenterol Hepatol 1995; 10:215–232.PubMedGoogle Scholar
  37. 37.
    Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708–710.CrossRefPubMedGoogle Scholar
  38. 38.
    Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7:971–994.Google Scholar
  39. 39.
    Riccabona G, Decristoforo C. Peptide targeted imaging of cancer. Cancer Biother Radiopharm 2003; 18:675–687.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Jean Claude Reubi
    • 1
    Email author
  • Meike Körner
    • 1
  • Beatrice Waser
    • 1
  • Luca Mazzucchelli
    • 1
    • 2
  • Louis Guillou
    • 3
  1. 1.Division of Cell Biology and Experimental Cancer Research, Institute of PathologyUniversity of BerneBerneSwitzerland
  2. 2.Institute of PathologyLocarnoSwitzerland
  3. 3.Institute of PathologyUniversity of LausanneLausanneSwitzerland

Personalised recommendations